|
|
|
| The effect of 5-HT Reuptake Inhibitors on Sleep Quality and Clinical Efficacy in Depression Patients |
| YANG Xiaozhong, MA Wenxia |
| The Second Affiliated Hospital of Xi'an Medical College, Shaanxi Xi'an 710038, China |
|
|
|
|
Abstract Objective: To investigate the effect of 5-HT reuptake inhibitors on sleep quality and clinical efficacy in patients with depression. Methods: From June 2016 to May 2018, 124 patients with moderate to severe depression were selected as subjects. They were divided into experimental group (68 cases) and control group (56 cases) by random number table. Patients in the experimental group were treated with 5-HT reuptake inhibitor (SRI), and patients in the control group were treated with tricyclic antidepressants. The overall effectiveness and the Pittsburgh Sleep Quality Index (PSQI), Hamilton Depression Scale (HAMD) and Self-rating Depression Scale (SDS) scores of the two groups after 1, 2 and 4 weeks of treatment were comparative analyzed. Results The overall effective rates of patients in the experimental group after 1, 2 and 4 weeks of treatment were 85.29%, 92.65% and 97.05%, respectively, which were significantly higher than that in the control group with the overall effective rates after treatment were 73.21%, 82.14% and 89.29%, respectively. The difference was statistically significant (P<0.05). In addition, the Pittsburgh Sleep Quality Index (PSQI), Hamilton Depression Scale (HAMD), and Self-rating Depression Scale (SDS) scores were significantly lower in the experimental group than that in the control group after 1, 2 and 4 weeks of treatment and the long-term efficacy of the experimental group was better after treatment for different periods of time. The difference were statistically significant (P<0.05). Conclusion: 5-HT reuptake inhibitors have significant clinical efficacy and safety in patients with depression, which could effectively relieve patients' depressive symptoms and improve their sleep quality, providing a strong theoretical basis for improving the quality of life of depression patients in the future, is worthy for clinical promotion and application.
|
|
|
|
|
|
[1] Arend J, Kegler A, Caprara A, et al. Depressive, inflammatory, and metabolic factors associated with cognitive impairment in patients with epilepsy[J]. Epilepsy Behav,2018, 86: 49~57.
[2] Dwivedi Y. MicroRNAs in depression and suicide: Recent insights and future perspectives[J].Affect Disord,2018, 240: 146~154.
[3] Sohn E. How to handle the dark days of depression[J]. Nature,2018, 557(7704): 267~269.
[4] 刘欢,王海军,高明周.基于抑郁症临床诊断标准的病机探讨[J].中华中医药杂志,2016,(7):2499~2501.
[5] 张朝辉,赵琳,任慧聪.不同频率重复经颅磁刺激对慢性应激抑郁模型大鼠行为的影响[J].郑州大学学报(医学版),2015,(4):477~481.
[6] Gaffrey M S, Tillman R, Barch D M,et al.Continuity and stability of preschool depression from childhood through adolescence and following the onset of puberty[J]. Compr Psychiatry,2018, 86: 39~46.
[7] Srinivasan R, Walker S, Wakefield J. Cognitive behavioural therapy, short-term psychoanalytical psychotherapy and brief psychosocial intervention are all effective in the treatment of depression in adolescents[J]. Arch Dis Child Educ Pract Ed,2018.
[8] Woo H I, Lim S W, Myung W,et al.Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis[J]. Exp Mol Med,2018, 50(8): 92.
[9] Buckman J, Underwood A, Clarke K,et al.Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis[J]. Clin Psychol Rev,2018, 64: 13~38. |
|
|
|
2018, Vol. 24 
